401 related articles for article (PubMed ID: 11118050)
1. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
[TBL] [Abstract][Full Text] [Related]
2. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy.
Goshorn S; Sanderson J; Axworthy D; Lin Y; Hylarides M; Schultz J
Cancer Biother Radiopharm; 2001 Apr; 16(2):109-23. PubMed ID: 11385958
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
[TBL] [Abstract][Full Text] [Related]
5. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
8. From IgG monoclonals to IgM-like molecules.
Ernst M; Meier D; Sonneborn HH
Hum Antibodies; 1999; 9(3):165-70. PubMed ID: 10690630
[TBL] [Abstract][Full Text] [Related]
9. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
[TBL] [Abstract][Full Text] [Related]
11. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
12. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
13. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
[TBL] [Abstract][Full Text] [Related]
14. Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli.
Hu X; O'Dwyer R; Wall JG
J Biotechnol; 2005 Oct; 120(1):38-45. PubMed ID: 16019098
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
17. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
18. Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg.
Yang X; Hu W; Li F; Xia H; Zhang Z
Protein Expr Purif; 2005 Jun; 41(2):341-8. PubMed ID: 15866720
[TBL] [Abstract][Full Text] [Related]
19. Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli.
Choi GH; Lee DH; Min WK; Cho YJ; Kweon DH; Son DH; Park K; Seo JH
Protein Expr Purif; 2004 May; 35(1):84-92. PubMed ID: 15039070
[TBL] [Abstract][Full Text] [Related]
20. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
